Clinical Trials Logo

Filter by:
NCT ID: NCT05967663 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study)

Start date: November 11, 2023
Phase: N/A
Study type: Interventional

It is a prospective, multicenter, randomised controlled, open-label, blinded endpoint assessment trial, to compare the strategy of immediate complete revascularisation and staged complete revascularisation in ST-segment-elevation myocardial infarction patients with multivessel coronary disease.

NCT ID: NCT05967546 Not yet recruiting - Arrhythmia Clinical Trials

Deep Learning for Intelligent Identification of Arrhythmias

ECG-LEARNING
Start date: December 30, 2024
Phase:
Study type: Observational

This study aims to design and train a deep learning model for the diagnosis of different arrhythmias.

NCT ID: NCT05967520 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

Start date: September 21, 2023
Phase: Phase 2
Study type: Interventional

The trial will evaluate pharmacodynamics,pharmacokinetics,safety,and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.

NCT ID: NCT05967325 Recruiting - Safety Issues Clinical Trials

SVF Combined With Functional Self-assembling Peptide Nanofiber Hydrogels in the Treatment of Spinal Cord Injury

Start date: July 15, 2023
Phase: N/A
Study type: Interventional

Traumatic spinal cord injury (SCI) is a severe medical problem experienced by people worldwide with high mortality and long term morbidity. Although progress has been made in understanding cellular and molecular mechanisms of SCI, treatment and management protocols aimed at ameliorating neurologic damage in patients remain ineffective. Cells and biomaterials offer new hope for the treatment of SCI. Up to now, there have been many studies on the treatment of SCI using cells and biomaterials. Stromal Vascular Fraction (SVF) is a heterogeneous mixture of cells obtained from adipose tissue. These cells include adipose-derived stem cells, endothelial cells, endothelial progenitor cells, pericytes, T cells, and other immune cells. SVF has strong self-renewal, proliferation and differentiation potential, it can replace necrotic cells and synthesize a variety of bioactive factors through paracrine and autocrine, activate cell and vascular regeneration pathways. Therefore, SVF shows significant advantages. The sequence of functional self-assembling peptide nanofiber hydrogels (hereinafter referred to as hydrogels) is HGF(RADA)4RIKVAV (H: histidine; G: Glycine; F: phenylalanine; R: arginine; A: Alanine; D: aspartic acid; I: isoleucine; K: Lysine; V: valerine). The hydrogel is based on the short peptide RADA16 ((RADA)4, which is already available in the product PuramatrixTM for clinical hemostasis and cell culture, but the aqueous solution of PuramatrixTM is acidic which harms cells and tissues upon direct contact. While the hydrogels in this study is pH neutral and does not harm cells and tissues. Articles published by the provider demonstrate that hydrogels can support 3D stem cell growth, have good biocompatibility in vivo (animal spinal cord), and promote neural regeneration after SCI. The chemical structure of the hydrogels is simple and clear, and the degradation product is amino acid. Therefore, SVF and the hydrogel from functional self-assembling peptide are combined for SCI repair in the study.

NCT ID: NCT05966792 Recruiting - Clinical trials for Polycystic Ovary Syndrome

SGLT2 Inhibitors in Treating Patients With PCOS

Start date: November 10, 2023
Phase: Phase 4
Study type: Interventional

Chronic inflammation is the core of Polycystic ovary syndrome (PCOS), and obesity and overweight further exacerbate the level of inflammation in the peripheral circulation and ovarian tissue in PCOS patients. Metformin is a classic endocrine drug for the treatment of PCOS, but its clinical response rate is only about 40%. Our previous published study (Diabetes Obes Metab, 2022) observed that the new hypoglycemic drug SGLT-2 inhibitor can significantly improve the clinical symptoms of patients with insulin resistance PCOS, and the clinical efficacy is not inferior to metformin, but its specific mechanism of action is not clear. Recent studies have shown that SGLT-2 significantly attenuates the activation of the Nod-like receptor protein 3 (NLRP3) inflammasomes and the secretion of IL-1β in patients with type 2 diabetes mellitus at high risk of cardiovascular disease. Based on the above research background, this project will combine clinical research and mechanism exploration to solve the following two problems: 1. whether SGLT2 inhibitor can further improve the clinical efficacy of PCOS patients compared to metformin; 2. mechanistic studies further clarify whether SGLT2 inhibitors improve inflammatory symptoms by modulating NLRP3 inflammosomes in the treatment of polycystic ovary syndrome;

NCT ID: NCT05966714 Active, not recruiting - Clinical trials for Neonatal Encephalopathy

Neonatal Cerebral Oxygenation and Electrical Activity at Different Altitude Levels

Start date: June 30, 2023
Phase:
Study type: Observational

In this study, the objective is to compare neonatal cerebral oxygenation and electrical activity within 3 days after birth across different altitude areas using non-invasive methods, specifically near infrared spectroscopy (NIRS) and amplitude-integrated electroencephalography (aEEG), and establish reference value for each altitude level.

NCT ID: NCT05966701 Not yet recruiting - Arthritis, Gouty Clinical Trials

The MAD Study of SSGJ-613 in Healthy Subjects

Start date: August 10, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.

NCT ID: NCT05966389 Recruiting - Cardiac Arrest Clinical Trials

Functional MRI to Assess Brain Damage in Cardiac Arrest Patients

Start date: January 1, 2021
Phase:
Study type: Observational

This is a single-center, observational study. Patients after successful cardiopulmonary resuscitation (CPR) will be transferred to the emergency intensive care unit for further standardized management. After successful return of spontaneous circulation (ROSC) for 72h and hemodynamics remained stable for 24h, the post-resuscitated patients underwent functional magnetic resonance imaging (fMRI) examination. During the examination, the supervising physician accompanied the patient and monitored the patient's vital signs using a magnetic resonance monitoring system (Siemens Healthcare Prism, Germany). Patients who are on ventilators are mechanically ventilated using a magnetic ventilator (HAMILTON-MRI, USA). In additional to conventional sequences, fMRI is performed for diffusion-prepared pseudo-continuous arterial spin labeling (DP-pCASL) and blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI). These MRI sequences allow quantitative assessment of the patients' cerebral microcirculation, blood-brain barrier, and cerebral oxygenation status. Patients will be followed up for neurologic prognosis according to the Modified Rankin Scale (mRS) at 6 months after disease onset.

NCT ID: NCT05966272 Active, not recruiting - Type 2 Diabetes Clinical Trials

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Start date: August 12, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

NCT ID: NCT05965882 Recruiting - Clinical trials for Cardiovascular Diseases

A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )

Start date: June 2016
Phase:
Study type: Observational

The registry study aims to discover biomarkers for accurate classification and risk assessment of ischemic heart disease.